Table 1.

Patient characteristics.

		N	%
Total		67
Median age (range)
≥18years	33 (18–72)	53
<18 years:	10.4 (3–16)	14
Sex
Male		36	53
Female		28	41
Clinical conditions at Diagnosis
Bleeding		53	79
Febrile neutropenia		5	7
HCV		1	1.5
Transfusion
Blood Transfusion		66	98
Platelet transfusion		63	94
Organomegaly
Hepatomegaly		6	9
Splenomegaly		7	10
WBC count
WBC≥10 (x 109/L)		23	34
WBC<10 (x 109/L)		44	66
Platelet Count
≥40 (x 109/L)		16	24
<40 (x 109/L)		51	76
Sans Risk category
Low risk		11	16
Intermediate risk		33	49
High Risk		23	34
Total		67
Bone Marrow Cellularity
Hypocellular		26	39
Hypercellular		17	25
Normal cellular		24	36
FLT3-ITD (only in 14 patients)
Wild		11	79
FLT3-ITD mutation		3	21
Induction Treatment	n=62
Doxorubicin or Idarubicin + ATRA		51	82
Pediatric protocol		11	18
Induction Complications
Bleeding		11	18
Febrile neutropenia		26	42
Differentiation syndrome		7	11
Heart failure		1	1.6
Death during induction		3	4.47
Consolidation regimen	n=59
Doxorubicin + ATRA		47	80
Pediatric protocol		12	20
Consolidation Complication
Febrile neutropenia		9	15
Death		1	1.49
Maintenance treatment	n=58
Median survival mo		19.23
(95% CI)		(16.33–23.75)